高级检索
    谢聪颖, 刘嘉淇. Amivantamab联合lazertinib一线治疗EGFR敏感突变晚期NSCLC：评MARIPOSA研究[J]. 循证医学, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
    引用本文: 谢聪颖, 刘嘉淇. Amivantamab联合lazertinib一线治疗EGFR敏感突变晚期NSCLC：评MARIPOSA研究[J]. 循证医学, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
    shu
    XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
    Citation: XIE Cong-ying, LIU Jia-qi. Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer[J]. Journal of Evidence-Based Medicine, 2024, 24(1): 20-25. DOI: 10.12019/j.issn.1671-5144.2024.01.004
    shu

    Amivantamab联合lazertinib一线治疗EGFR敏感突变晚期NSCLC：评MARIPOSA研究

    Review of MARIPOSA Trial: Amivantamab Plus Lazertinib as First-Line Treatment in Patients With EGFR-Mutated Non-Small Cell Lung Cancer

      摘要
      • HTML全文
      • 参考文献(12)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回